NCH2 Stock Overview
Engages in the engineering, procurement, and construction of electrochemical plants in Germany, Italy, Japan, China, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
thyssenkrupp nucera AG & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.78 |
| 52 Week High | €22.94 |
| 52 Week Low | €7.68 |
| Beta | 0 |
| 11 Month Change | 0.051% |
| 3 Month Change | -17.44% |
| 1 Year Change | -57.05% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -58.44% |
Recent News & Updates
Shareholder Returns
| NCH2 | DE Construction | DE Market | |
|---|---|---|---|
| 7D | 13.3% | 0.7% | 2.7% |
| 1Y | -57.1% | -8.2% | 2.9% |
Return vs Industry: NCH2 underperformed the German Construction industry which returned -9% over the past year.
Return vs Market: NCH2 underperformed the German Market which returned 0.6% over the past year.
Price Volatility
| NCH2 volatility | |
|---|---|
| NCH2 Average Weekly Movement | 6.0% |
| Construction Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: NCH2's share price has been volatile over the past 3 months.
Volatility Over Time: NCH2's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1960 | 855 | Werner Ponikwar | thyssenkrupp-nucera.com |
thyssenkrupp nucera AG & Co. KGaA engages in the engineering, procurement, and construction of electrochemical plants in Germany, Italy, Japan, China, and internationally. The company offers green hydrogen, chlor- alkali, and hydrochloric acid solutions. It serves chemical and steel industries, as well as refineries.
thyssenkrupp nucera AG & Co. KGaA Fundamentals Summary
| NCH2 fundamental statistics | |
|---|---|
| Market cap | €1.23b |
| Earnings (TTM) | €5.70m |
| Revenue (TTM) | €771.30m |
216.6x
P/E Ratio1.6x
P/S RatioIs NCH2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NCH2 income statement (TTM) | |
|---|---|
| Revenue | €771.30m |
| Cost of Revenue | €686.70m |
| Gross Profit | €84.60m |
| Other Expenses | €78.90m |
| Earnings | €5.70m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.045 |
| Gross Margin | 10.97% |
| Net Profit Margin | 0.74% |
| Debt/Equity Ratio | 0% |
How did NCH2 perform over the long term?
See historical performance and comparison